NCT05071014 - A Study of Pembrolizumab and Cryoablation in People With Mesothelioma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 24, 2021

Primary Completion Date

December 18, 2023

Study Completion Date

December 18, 2023

Conditions

Lung CancerUnresectable Mesothelioma

Interventions

DRUG

Pembrolizumab

Pembrolizumab: 200mg/dose delivered by IV infusion

PROCEDURE

Image-guided cryoablation

Cryoablation will be used to treat a designated lesion with preference given to a lesion that is symptomatic or at risk of causing symptoms. Per institutional standards, complete ablation of the lesion will be attempted.

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center (All protocol activities), New York

10604

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited protocol activities), Uniondale

11725

Memorial Sloan Kettering Commack (Limited protocol activities), Commack

07920

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors

lead

Memorial Sloan Kettering Cancer Center

OTHER